Modis Therapeutics competitorsClear all

Amicus Therapeutics's top competitors include Bluebird Bio, Ultragenyx Pharmaceutical and Polyplus-transfection.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Bluebird Bio
Bluebird Bio
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Polyplus-transfection
Polyplus-transfection
Polyplus-transfection is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics.
Founding Date
Founding Date
2002
Founding Date
1992
Founding Date
2010
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Philadelphia, US HQ
Northbridge, AU
Pointe Claire, CA
Paris, FR
München, DE
Dublin, IE
Milano, IT
see more
Locations
Cambridge, US HQ
Paris, FR
München, DE
Athens, GR
Milano, IT
Utrecht, NL
Zug, CH
see more
Locations
Novato, US HQ
Locations
Illkirch-Graffenstaden, FR HQ
New York, US
Employees
Employees
58415% increase
Employees
1,2134% increase
Employees
74021% increase
Employees
1142% increase
Valuation ($)
Valuation ($)
3 b
Valuation ($)
290.2 m
Valuation ($)
4.1 b
Valuation ($)
N/A
Twitter followers
Twitter followers
2 k
Twitter followers
10.1 k
Twitter followers
N/A
Twitter followers
250
Number of tweets (last 30 days)
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
17
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
7
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
4.4
Average likes per tweet (last 30 days)
7.8
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
0.6
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
71.43%
Alexa Website Rank
Alexa Website Rank
432054
Alexa Website Rank
513212
Alexa Website Rank
N/A
Alexa Website Rank
656900
Employee Rating
Employee Rating
2.9
Employee Rating
3.6
Employee Rating
4.4
Employee Rating
4.8

Financial

Revenue (est.)
Revenue (est.)
$260.9m (FY, 2020)
Revenue (est.)
$250.7m (FY, 2020)
Revenue (est.)
$271m (FY, 2020)
Revenue (est.)
N/A
Cost of goods
Cost of goods
$31m (FY, 2020)
Cost of goods
$5.4m (FY, 2020)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$229.8m (FY, 2020)
Gross profit
$245.3m (FY, 2020)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($276.9m) (FY, 2020)
Net income
($618.7m) (FY, 2020)
Net income
($186.6m) (FY, 2020)
Net income
N/A

Funding

Total funding raised
Total funding raised
$ 88m
Total funding raised
$ 409m
Total funding raised
$ 200.1m
Total funding raised
$ 3.2m
For sources of this data, please see the company profile

View company profiles

Bluebird Bio
HQ
Cambridge, US
Employees
1,213↑ 4% increase

Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.

View company
Ultragenyx Pharmaceutical
HQ
Novato, US
Employees
740↑ 21% increase

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

View company
Polyplus-transfection
HQ
Illkirch-Graffenstaden, FR
Employees
114↑ 2% increase

Polyplus-transfection is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics.

View company